Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Euthyroid Sick Syndrome Precipitated By Rapid Weight Loss Following Semaglutide Initiation: A Case Report.

Elmezayen ZW, Qrareya F, Abdallah A, Salameh H, Qaisi W

Clinical medicine insights. Endocrinology and diabetes22 Apr 2026

PMID42052217 (opens in a new tab)PMCIDPMC13111885 (opens in a new tab)DOI10.1177/11795514261443862 (opens in a new tab)PepBankPUB-42052217
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 54-year-old woman, monthly semaglutide titration over 4 months was followed by weight loss of 22 kg.

    In plain wordsOne woman lost 22 kg over 4 months while semaglutide was raised each month.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss during titration
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Weight loss
    22 kg
    4 months

    Source sentences

    Summary
    The dose was titrated monthly over 4 months, during which she experienced significant weight loss of 22 kg.
    1 context sentence
    Summary · context
    A 54-year-old woman presented to the endocrinology clinic with a 4-month history of progressive fatigue, lethargy, and new-onset cold intolerance after initiation of semaglutide for weight management.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with rapid weight loss after semaglutide initiation, laboratory tests showed low free T3, a pattern of euthyroid sick syndrome.

    In plain wordsOne woman who lost weight quickly on semaglutide had a low level of the thyroid hormone T3, without thyroid disease.

    Peptide
    Semaglutide
    Outcome
    DecreaseLow free T3
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation revealed a thyroid function profile classic for ESS, with low free T3, low-normal free T4, and a normal thyroid-stimulating hormone (TSH) level that was inappropriately low relative to the reduced T3.
    1 context sentence
    Summary · context
    A 54-year-old woman presented to the endocrinology clinic with a 4-month history of progressive fatigue, lethargy, and new-onset cold intolerance after initiation of semaglutide for weight management.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with rapid weight loss after semaglutide initiation, free T4 was low-normal and TSH was normal but inappropriately low relative to the reduced T3.

    In plain wordsOne woman on semaglutide had low-normal thyroxine and a normal thyroid-stimulating hormone level that was too low for her T3.

    Peptide
    Semaglutide
    Outcome
    MixedThyroid profile consistent with euthyroid sick syndrome
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Laboratory evaluation revealed a thyroid function profile classic for ESS, with low free T3, low-normal free T4, and a normal thyroid-stimulating hormone (TSH) level that was inappropriately low relative to the reduced T3.
    1 context sentence
    Summary · context
    A 54-year-old woman presented to the endocrinology clinic with a 4-month history of progressive fatigue, lethargy, and new-onset cold intolerance after initiation of semaglutide for weight management.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.